SABIC Reports Successful Step Towards Creating Circular Polymers Based On Advanced Recycling of Used Medical Plastic

Collaboration with dialysis department at Jessa Hospital, Belgium, in proof-of-concept pilot project. Project has shown that non-contaminated used medical plastic can be repurposed for advanced recycling and subsequent production of medical grade polymers as part of SABIC’s TRUCIRCLE™ portfolio. The pilot project could be translated into other regions

SABIC

SABIC, a global leader in the chemical industry, has successfully demonstrated the feasibility of recycling used medical plastic back into the medical materials stream. The project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium. Serving as a pilot proof-of-concept, used medical plastic generated at Jessa’s hospital was converted to pyrolysis oil in an advanced recycling process, delivering circular feedstock for SABIC’s production of TRUCIRCLE™ polymers in medical grade quality with same performance, purity and physiological safety as virgin-based medical grade polymers. This is indispensable for medical approvals by regulators.

Lada Kurelec, General Manager, Polymers Technology & Innovation at SABIC, states:

“Working with Jessa Hospital has been an immensely rewarding experience, where we learned how individual belief in circularity can mobilize industry to work together. I value how this collaboration enabled creation of an ecosystem to collect and recycle non-contaminated medical waste in a very short time. Thanks to this collaboration, we are creating a certified circular TRUCIRCLE™ polymer portfolio able to serve the healthcare market. We are inviting other players in the value chain and in other regions to join us and Jessa in this ground-breaking initiative to accelerate the circularity of plastics in the medical industry.”

Advanced recycling technology and the vast experience gained through its TRUCIRCLE™ solutions put SABIC in a strong position to provide a circular solution designed to help Jessa Hospital reduce the environmental footprint of its medical products by avoiding their incineration after use. Approximately 85% of the used medical plastic generated at the hospital is not contaminated and therefore requires no specialized treatment. This allows it to be repurposed as feedstock for advanced recycling and subsequent production of high-quality medical grade polymers, saving virgin raw material and contributing to a more circular medical economy.

Karl Zwinnen, Project Engineer at Jessa adds:

“We are very pleased with the advanced and circular recycling approach enabled by SABIC to improve our medical waste management. The setup of an efficient collection system for used medical plastic has met with strong support among our medical and healthcare staff. Besides contributing to enhanced sustainability and circularity, the solution also has an enormous potential for reducing our disposal costs. We look forward to implementing it across all Jessa locations.”

As a result of this successful pilot project, SABIC is currently in the process of actively engaging partners to scale up operations and create a fully closed-loop recycling model for used medical plastic in larger volumes. Furthermore, there is the potential to initiate other similar pilot projects in other countries including the United States.

Circular Materials

SABIC’s certified circular materials are produced using mass balance accounting according to the International Sustainability & Carbon Certification (ISCC) PLUS program, which defines a set of transparent rules for tracking the material flow across complex supply chains from the feedstock to final applications. The resulting certified circular polymers form part of the company’s TRUCIRCLE™ portfolio and services.

TRUCIRCLE™ Portfolio

SABIC’s TRUCIRCLE™ portfolio and services include certified circular polymers as well as design for recyclability, mechanically recycled products, certified renewable polymers from bio-based feedstock, and closed loop initiatives to recycle plastic back into high-quality applications and help prevent valuable used plastics from becoming waste.

SourceSABIC

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version